Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigue

Poly(ADP-ribose) polymerase inhibitors (PARPi) have dramatically changed treatment for advanced ovarian cancer, but nearly half of patients experience significant fatigue. We conducted a two-site pilot randomized trial to evaluate the feasibility, acceptability, and preliminary efficacy of a brief,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gynecologic oncology 2023-10, Vol.177, p.165-172
Hauptverfasser:	Wright, Alexi A., Poort, Hanneke, Tavormina, Anna, Schmiege, Sarah J., Matulonis, Ursula A., Campos, Susana M., Liu, Joyce F., Slivjak, Elizabeth T., Gilmour, Anna L., Salinger, Julia M., Haggerty, Ashley F., Arch, Joanna J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acceptance Acceptance and commitment therapy Distress Dose reduction Fatigue Ovarian cancer PARP inhibitors Psychosocial intervention Side effects Symptoms Telehealth
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Poly(ADP-ribose) polymerase inhibitors (PARPi) have dramatically changed treatment for advanced ovarian cancer, but nearly half of patients experience significant fatigue. We conducted a two-site pilot randomized trial to evaluate the feasibility, acceptability, and preliminary efficacy of a brief, acceptance-based telehealth intervention (REVITALIZE) designed to reduce fatigue interference in patients on PARPi. From June 2021 to April 2022, 44 participants were randomized 1:1 to REVITALIZE (6 weekly one-on-one sessions+booster) or enhanced usual care. Feasibility was defined as: ≥50% approach-to-consent among potentially eligible patients and ≥70% completion of 12-week follow-up assessment; acceptance was
ISSN:	0090-8258 1095-6859 1095-6859
DOI:	10.1016/j.ygyno.2023.08.020